Antiviral Drugs Market size to reach USD 89.4 billion by 2035

The global antiviral drugs market was valued at USD 62 billion in 2025 and is expected to grow from USD 63.6 billion in 2026 to USD 89.4 billion in 2035, at a CAGR of 3.9% during the forecast period, according to the latest report published by Global Market Insights Inc.

Rising Prevalence of Viral Infections

The increasing incidence of viral infections across the world continues to drive demand for effective antiviral therapies. Growing awareness of early diagnosis, improved access to healthcare services, and the expanding burden of both acute and chronic viral diseases have encouraged greater adoption of antiviral drugs in hospitals, clinics, and outpatient settings.

Increasing Number of Product Launches for HIV Treatment

The continuous introduction of new HIV therapies is supporting market growth by expanding treatment options and improving patient outcomes. Pharmaceutical companies are focusing on innovative formulations, combination therapies, and long-acting treatment solutions that enhance treatment adherence, reduce dosing frequency, and address evolving clinical needs.

Emerging Drug Resistance

The growing emergence of antiviral drug resistance remains a major challenge for the market. Genetic mutations in viruses can reduce the effectiveness of existing therapies, creating the need for continuous research, development of novel antiviral agents, and more advanced treatment strategies, while also increasing overall healthcare costs.

Browse key industry insights spread across 139 pages with 189 market data tables and figures from the report, Antiviral Drugs Market Size By – Drug Class (Reverse Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug Classes), By Indication (HIV/AIDS, Hepatitis, Coronavirus Infection, Herpes Simplex Virus (HSV), Influenza, Other Indications), By Type (Branded, Generic), By Route of Administration (Oral, Parenteral, Topical, Other Routes of Administration), By Age Group (Geriatric, Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Global Forecast” in detail, along with the table of contents: https://www.gminsights.com/industry-analysis/antiviral-drugs-market

Reverse Transcriptase Inhibitors to Gain Traction

The reverse transcriptase inhibitors segment accounted for 29.9% share and was valued at USD 18.6 billion in 2025. The segment maintained a leading position due to the rising prevalence of HIV/AIDS and the critical role these therapies play in antiretroviral treatment. Reverse transcriptase inhibitors, including nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), remain fundamental to long-term HIV management by suppressing viral replication and slowing disease progression.

Branded Drugs to Drive Market Growth

The branded segment held around 71.8% share of antiviral drugs market in 2025. Branded antiviral drugs continued to dominate the market owing to their proven safety, efficacy, and quality, supported by extensive research, clinical development, and regulatory approvals. These therapies are widely preferred for the treatment of chronic viral infections that require long-term disease management and consistent therapeutic outcomes.

North America to Propel Market Growth

North America antiviral drugs market held 40.1% share in 2025. Regional market leadership was supported by a well-established healthcare infrastructure, substantial investments in pharmaceutical research and development, and strong demand for advanced antiviral therapies. High adoption of innovative treatment options, favorable reimbursement frameworks, and widespread access to modern diagnostic technologies continued to support market expansion.

Some of the leading companies operating in the global antiviral drugs market include Gilead Sciences, Pfizer, Merck, F. Hoffmann-La Roche, GlaxoSmithKline, Johnson & Johnson, Takeda Pharmaceutical, AbbVie, AstraZeneca, Novartis, Bristol-Myers Squibb, Viatris, Sun Pharmaceutical, Cipla, Dr. Reddy's Laboratories, and Aurobindo Pharma.

Companies operating in the antiviral drugs market are strengthening their market position through continuous investment in research and development to introduce innovative therapies with improved efficacy and safety profiles. They are expanding product portfolios by developing combination treatments and next-generation antiviral drugs targeting multiple viral infections. Strategic collaborations, licensing agreements, and acquisitions help companies accelerate product development and broaden their global presence.

In June 2026, Qubigen announced a collaborative initiative focused on decentralized federated AI driven design of antiviral compounds to accelerate the discovery of next generation antiviral therapies.